Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656331 | 0.89 | PDE5A (0.40) | PDE5AGABRA3HSD17B10GABRG2GABRB3 | |
| SCHEMBL2660673 | 0.88 | HDAC1 (0.34) | PDE5AGABRG2GABRB3GABRA2GRM2 | |
| SCHEMBL2661341 | 0.85 | GABRG2 (0.38) | PDE5AGABRA3GABRG2GABRB3GABRA2 | |
| SCHEMBL2658808 | 0.85 | GABRG2 (0.44) | PDE5AGABRG2GABRB3GABRA2GRM2 | |
| SCHEMBL2656682 | 0.85 | GABRG2 (0.36) | PDE5AGABRA3GABRG2GABRB3GABRA2 | |
| SCHEMBL2661405 | 0.84 | GABRG2 (0.42) | PDE5AGABRG2GABRB3GABRA2GRM2 | |
| SCHEMBL2657693 | 0.84 | LCK (0.34) | — | |
| SCHEMBL2655630 | 0.84 | GABRG2 (0.39) | PDE5AGABRA3GABRG2GABRB3GABRA2 | |
| SCHEMBL2656693 | 0.83 | PDE5A (0.34) | PDE5A | |
| SCHEMBL2660986 | 0.82 | PDE5A (0.33) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | PDE5A 742/4885GABRA3 216/4885NLRP3 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.